Candel Therapeutics, Inc. (CADL) vs Design Therapeutics, Inc. (DSGN)
A side-by-side comparison of Candel Therapeutics, Inc. and Design Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CADL
Candel Therapeutics, Inc.
$10.28HealthcareDelayed quote: Oct 6, 2026, 11:35 AM EDT
DSGN
Design Therapeutics, Inc.
$12.34HealthcareDelayed quote: Oct 6, 2026, 11:35 AM EDT
Total return — CADL vs DSGN
growth of $100 · dividends reinvested · last 5yCADL +46.1% (+7.9%/yr)DSGN -19.1% (-4.2%/yr)CADL compounded faster over this window
CADL DSGN
CADL vs DSGN: by the numbers
- •DSGN is the larger company ($771M vs $753M market cap).
Metrics side by side
Valuation
| Metric | CADL | DSGN |
|---|---|---|
| P/B ratio | 5.97 | 3.82 |
Profitability
| Metric | CADL | DSGN |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -70.19% | -35.07% |
| ROIC | -36.83% | -38.92% |
Growth (annualized)
| Metric | CADL | DSGN |
|---|---|---|
| Total return CAGR (5Y) | -1.42% | -3.82% |
Frequently asked
- How have CADL and DSGN total returns compared?
- Over the past 5 years, CADL delivered -1.42% and DSGN delivered -3.82% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.